A new study finds the orexin-receptor antagonist is effective in the elderly, reports Neurology Advisor.

Compared with placebo, 30 mg of suvorexant improved PRO and PSG measures of sleep maintenance and sleep onset at the earliest time points, including the first week for PRO and the first night for PSG measures, and at three months (P<.05). Comparable results were reported with the 15-mg dose, with the exception of three-month PRO (P=.05) and PSG onset measures (P=.09).